Evidence map›Paper›PMID 25899407›Full record

ArticleJournal of extracellular vesicles2015

Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting.

Oscar P B Wiklander, Joel Z Nordin, Aisling O'Loughlin, Ylva Gustafsson, Giulia Corso, Imre Mäger, Pieter Vader, Yi Lee, Helena Sork, Yiqi Seow and 8 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Journal of extracellular vesicles, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06002841 (Extracellular Vesicles From Mesenchymal Cells in the Treatment of Acute Respiratory Failure Associated With SARS-CoV-2 and Other Etiologies), which is not on this map. Cited by 993 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
993citing papers in PubMed, 4 pooled it
30.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06002841 phase1 / phase2unknown statusnot on this mapstarted 2024, after this paper: background citation

Extracellular Vesicles From Mesenchymal Cells in the Treatment of Acute Respiratory Failure Associated With SARS-CoV-2 and Other Etiologies: a Clinical Trial, Randomized, Double-blind.

TypeinterventionalSponsorD'Or Institute for Research and EducationRan2024 to 2025Enrolled15ConditionsSevere Acute Respiratory Syndrome (SARS), Acute Respiratory Distress Syndrome (ARDS), PneumoniaArmsintravenous treatment with EVs, intravenous treatment with placebo solution
3 · Its place in the literature

Who cites it

993 citing papers in PubMed, 4 syntheses or guidelines pooled it, 1,609 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Biology and Therapeutic Potential of Exosomes, Targeted Drug Delivery.International journal of molecular sciences · 2026
    Review
  19. Review
  20. Review

933 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 5 countries.

Oscar P B WiklanderDepartment of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Joel Z NordinDepartment of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Aisling O'LoughlinDepartment of Physiology, Anatomy and Genetics, University of Oxford, Oxford, United Kingdom.
Ylva GustafssonAdvanced Centre for Translational Regenerative Medicine, Department for Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Giulia CorsoDepartment of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Imre MägerDepartment of Physiology, Anatomy and Genetics, University of Oxford, Oxford, United Kingdom.
Pieter VaderDepartment of Physiology, Anatomy and Genetics, University of Oxford, Oxford, United Kingdom.
Yi LeeDepartment of Physiology, Anatomy and Genetics, University of Oxford, Oxford, United Kingdom.
Helena SorkDepartment of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Yiqi SeowMolecular Engineering Laboratory, Agency for Science, Technology and Research (A*STAR), Singapore.
Nina HeldringDepartment of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Lydia Alvarez-ErvitiDepartment of Clinical Neuroscience, Institute of Neurology, University College London, London, United Kingdom.
C I Edvard SmithDepartment of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Katarina Le BlancDepartment of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Paolo MacchiariniAdvanced Centre for Translational Regenerative Medicine, Department for Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Philipp JungebluthAdvanced Centre for Translational Regenerative Medicine, Department for Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Matthew J A WoodDepartment of Physiology, Anatomy and Genetics, University of Oxford, Oxford, United Kingdom.
Samir El AndaloussiDepartment of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Karolinska Institutet · SEUniversity of Oxford · GBScience for Life Laboratory · SEAgency for Science, Technology and Research · SGHeidelberg University · DEUniversity College London · GBUniversity of Tartu · EE

Funding

Parkinson's UK G-1109
6 · The paper itself

Abstract

Extracellular vesicles (EVs) have emerged as important mediators of intercellular communication in a diverse range of biological processes. For future therapeutic applications and for EV biology research in general, understanding the in vivo fate of EVs is of utmost importance. Here we studied biodistribution of EVs in mice after systemic delivery. EVs were isolated from 3 different mouse cell sources, including dendritic cells (DCs) derived from bone marrow, and labelled with a near-infrared lipophilic dye. Xenotransplantation of EVs was further carried out for cross-species comparison. The reliability of the labelling technique was confirmed by sucrose gradient fractionation, organ perfusion and further supported by immunohistochemical staining using CD63-EGFP probed vesicles. While vesicles accumulated mainly in liver, spleen, gastrointestinal tract and lungs, differences related to EV cell origin were detected. EVs accumulated in the tumour tissue of tumour-bearing mice and, after introduction of the rabies virus glycoprotein-targeting moiety, they were found more readily in acetylcholine-receptor-rich organs. In addition, the route of administration and the dose of injected EVs influenced the biodistribution pattern. This is the first extensive biodistribution investigation of EVs comparing the impact of several different variables, the results of which have implications for the design and feasibility of therapeutic studies using EVs.

Indexed as

biodistributiondrug deliveryexosomesextracellular vesiclesmicrovesiclesnanotechnologytissue targeting

Identifiers

PMID25899407
PMCPMC4405624
OpenAlexW2071625709

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.